Information:
Error:
ID
23952
Description
An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT00516048
Link
https://clinicaltrials.gov/show/NCT00516048
Keywords
Versions (1)
- 7/19/17 7/19/17 -
Uploaded on
July 19, 2017
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Type 2 Diabetes Mellitus NCT00516048
Eligibility Type 2 Diabetes Mellitus NCT00516048
- StudyEvent: Eligibility
Similar models
Eligibility Type 2 Diabetes Mellitus NCT00516048
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
ID.1
Item
diagnosed with type 2 diabetes.
boolean
C0011860 (UMLS CUI [1])
ID.2
Item
have been exposed to exenatide for at least 3 months in previous amylin/lilly studies h8o-mc-gwao, h8o-mc-gwap, h8o-mc-gwat, or h8o-mc-gwba.
boolean
C0167117 (UMLS CUI [1])
ID.3
Item
have interrupted exenatide treatment for a period of at least 2 months.
boolean
C0167117 (UMLS CUI [1])
ID.4
Item
hba1c of ≤10.5%.
boolean
C0019018 (UMLS CUI [1])
ID.5
Item
have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
boolean
C0087111 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,2])
ID.6
Item
have previously completed or withdrawn from this study.
boolean
C2348557 (UMLS CUI [1,1])
C2348571 (UMLS CUI [1,2])
C2348571 (UMLS CUI [1,2])
ID.7
Item
have taken marketed exenatide (byetta) during the interim period between studies gwao, gwap, gwat, or gwba and the current study.
boolean
C1636686 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,2])
ID.8
Item
used drugs for weight loss (for example, xenical® [orlistat], meridia® [sibutramine], acutrim® [phenylpropanolamine], accomplia® [rimonabant], or similar over-the-counter medications) within 3 months of screening.
boolean
C0376606 (UMLS CUI [1])
ID.9
Item
are currently treated with any of the following excluded medications: drugs that directly affect gastrointestinal motility, including, but not limited to: reglan®
boolean
C0034977 (UMLS CUI [1,1])
C0017184 (UMLS CUI [1,2])
C0017184 (UMLS CUI [1,2])
ID.10
Item
(metoclopramide), propulsid® (cisapride), and chronic macrolide antibiotics.
boolean
C0025853 (UMLS CUI [1,1])
C0722861 (UMLS CUI [1,2])
C0003240 (UMLS CUI [1,3])
C0722861 (UMLS CUI [1,2])
C0003240 (UMLS CUI [1,3])
ID.11
Item
use insulin with daily dosage exceeding 1 u/kg.
boolean
C0021641 (UMLS CUI [1])